drugset
drugset / Trial / NCT06038461

An Open, Single-center Clinical Study of Surufatinib Combined With Temozolomide and S-1 in the First-line Treatment of Advanced Neuroendocrine Tumors

NCT06038461 ↗

Phase 1/2 Recruiting 40 enrolled Cancer Institute and Hospital, Chinese Academy of Medical Sciences
NaSingle-groupOpen-labelTreatment

Summary

This is a prospective, open, single-center study evaluating the efficacy and safety of surufatinib Combined With Temozolomide and S-1 as the first-line treatment of advanced neuroendocrine tumors

Timeline

Start
2023-09-15
Primary completion
2026-09-15
Completion
2026-09-15

Drugs

EvaluationDrugModalityDoseRoute
Subject S-1 Small molecule 40 mg Oral
Subject S-1 Small molecule 60 mg Oral
Subject Surufatinib Small molecule 250 mg Oral
Subject Temozolomide Small molecule 200 mg Oral
Subject Temozolomide Small molecule 300 mg Oral

Indications

neuroendocrine neoplasm